Thrice-daily biphasic insulin aspart 30 may be another therapeutic option for Chinese patients with type 2 diabetes inadequately controlled with oral antidiabetic agents.
Yang
Wen-ying
WY
Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China. yangwenying1707@yahoo.com.cn
Ji
Qiu-he
QH
Zhu
Da-long
DL
Yang
Jin-kui
JK
Chen
Lu-lu
LL
Liu
Zhi-min
ZM
Yu
De-min
DM
Yan
Li
L
D061265:Biphasic Insulins; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D061267:Insulin Aspart; D007336:Insulin, Isophane; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D061265:Biphasic Insulins; D007004:Hypoglycemic Agents; D007328:Insulin; C557564:insulin aspart, insulin aspart protamine drug combination 30:70; D007336:Insulin, Isophane; D061267:Insulin Aspart